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OBJECTIVE — Our aim was to examine the effect of cyclooxygenase 2 (COX2) inhibition on
endothelial function in subjects with type 1 diabetes analyzed on the basis of renal ﬁltration
status.
RESEARCH DESIGN AND METHODS — Flow-mediated dilation (FMD) was deter-
mined in type 1 diabetic subjects and hyperﬁltration (glomerular ﬁltration rate 135 ml/min/
1.73 m
2, n  13) or normoﬁltration (glomerular ﬁltration rate 135 ml/min/1.73 m
2, n  11).
Studieswereperformedbeforeandaftercelecoxib(200mgdailyfor14days)duringeuglycemia
and hyperglycemia.
RESULTS — Baseline parameters were similar in the two groups. Pretreatment, FMD was
augmented in normoﬁltering versus hyperﬁltering subjects during clamped euglycemia (10.2
5.3% vs. 5.9  2.3%, P  0.003). COX2 inhibition suppressed FMD in normoﬁltering (10.2 
5.3%to5.83.4%,P0.006)versushyperﬁlteringsubjects(ANOVAinteraction,P0.003).
CONCLUSIONS — Systemic hemodynamic function, including the response to COX2 in-
hibition, is related to ﬁltration status in diabetic subjects and may reﬂect general endothelial
dysfunction.
Diabetes Care 33:1344–1346, 2010
R
enal hyperﬁltration is associated
with an increased risk of progres-
sion to diabetic nephropathy in
many, but not all, studies (1). Diabetic
hyperﬁltration may in part be due to cy-
clooxygenase 2 (COX2) upregulation
(2,3). We have previously identiﬁed a co-
hort of subjects with uncomplicated type
1 diabetes who exhibit hyperﬁltration
(glomerular ﬁltration rate [GFR] 135
ml/min/1.73m
2)ornormoﬁltration(GFR
135 ml/min/1.73 m
2) during clamped
euglycemia(4).Inhyperﬁlteringsubjects,
COX2 inhibition reduces GFR, whereas
in subjects with normoﬁltration, COX2
inhibition is associated with an opposite
GFR rise and an exaggerated suppression
of vasodilatory prostaglandins (4). To-
gether with previous observations (4–6),
these ﬁndings suggest that hyperﬁltering
and normoﬁltering individuals are physi-
ologically distinct.
Previous studies have suggested that
early type 1 diabetes is characterized by a
state of generalized vasodilation due to
nitric oxide upregulation (7). The role of
COX2 in the systemic vasculature in hu-
mans with early type 1 diabetes is, how-
ever, incompletely understood (8–11).
Accordingly, our goal was to study the
effect of COX2 inhibition on endothelial
function in diabetic subjects with hy-
perﬁltrationornormoﬁltration.Ourhy-
pothesis was that renal hemodynamic
differences would also be reﬂected in
the systemic circulation.
RESEARCH DESIGN AND
METHODS— Recruitment, study pro-
tocols, and renal hemodynamic data from a
subset of this cohort have been previously
described (supplementary Table A, avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
2340/DC1) (4). Experiments were carried
out on 2 consecutive days before (clamped
euglycemia [4–6 mmol/l] and hyper-
glycemia [9–11 mmol/l]) and repeated
after 14 days of COX2 inhibition (cele-
coxib,200mgdaily)(4).Circulatingin-
sulin levels were measured on each
study day (4).
Endothelial function was determined
byrecordingdiameterchangesinthebra-
chialarteryinresponsetoincreasedblood
ﬂowgeneratedduringreactivehyperemia
(ﬂow-mediateddilation[FMD])andglyc-
eryl trinitrate-induced dilation (GTN).
Longitudinal electrocardiograph-gated
end-diastolic images were acquired and
the arterial diameter was determined us-
ing automatic edge-detection software
(Vascular Tools, Coralville, IA). The right
brachialarterywasscanned2–5cmabove
the antecubital fossa using high-resolution
B-mode vascular ultrasound (Vivid 7; GE/
Vingmed, Milwaukee, WI). After baseline
images were recorded, the blood pressure
cuff was inﬂated around the forearm distal
to the elbow to 200 mmHg for 5 min.
After deﬂation, the change in vessel diame-
terinresponsetoreactivehyperemia(endo-
thelium-dependent dilation) was measured
forafurther5min.GTN(400g)wasthen
administered sublingually, and the changes
were measured over a further 5 min (endo-
thelium-independent dilation). FMD and
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mal percentage changes in vessel diameter
afterreactivehyperemiaandadministration
ofGTN,respectively,aswehavepreviously
described (12). The variability for repeated
measurements of arterial diameters at ﬂow-
mediated vasodilation was 0.01  0.0.005
mm (absolute diameter) or 0.26  0.01%
(% absolute value of brachial artery at
FMD), which is similar to previous reports
(13,14).
The data were analyzed based on renal
ﬁltration status. Between-group baseline
comparisons were made using parametric
methods (unpaired t test). Between-group
and within-group differences in hemody-
namic responses were determined by re-
peated-measures ANOVA. All statistical
analyses (meansSD) were performed us-
ing SPSS (version 14.0).
RESULTS— Baseline characteristics
were similar in the two groups (supple-
mentary Table B). Renal hemodynamic
function tests revealed expected differ-
ences in GFR. Within-group blood pres-
sure changes were not signiﬁcant, nor
were between-group blood pressure dif-
ferences (Table 1). Insulin concentrations
were similar throughout the study.
Before COX2 inhibition during
clamped euglycemia, FMD was higher in
normoﬁltering versus hyperﬁltering sub-
jects (P  0.003, Table 1). In response to
COX2 inhibition during clamped eugly-
cemia, FMD declined in normoﬁltering
subjects (P  0.006; ANOVA interaction
term for between-group effect, P 
0.003).Differenceswereabolishedbyhy-
perglycemia. GTN responsiveness was
similar in the two groups throughout the
study.
CONCLUSIONS— While selective
COX2 inhibition reduces hyperﬁltration,
the effect on FMD in humans with type 1
diabetes was until now unknown. Our
ﬁrst major ﬁnding was that during
clamped euglycemia, hyperﬁltering sub-
jectsexhibitedevidenceofimpairedFMD
compared with normoﬁlterers. Our re-
sults suggest that hyperﬁltering type 1 di-
abetic subjects may be additionally at risk
in that they demonstrated an impaired
ability to induce arterial vasodilation after
an ischemic stimulus compared with in-
dividuals with normoﬁltration.
Our second major observation was
that in contrast with hyperﬁltering sub-
jects, COX2 inhibition suppressed FMD
during clamped euglycemia in normoﬁl-
tering subjects, without impairing GTN
responsiveness. These ﬁndings in FMD
and GTN responsiveness suggest that the
observed differences may have been due
to endothelial cell rather than vascular
smooth muscle functional effects. While
COX2inhibitionmayreducerenalhyper-
ﬁltration in subjects with GFR 135 ml/
min/1.73 m
2) (4), we have previously
shown in normoﬁltering subjects an ex-
aggerated suppression of vasodilatory
prostaglandinsandrenalvasoconstriction
(4), and in this study, we show impaired
FMD.
Our study has limitations. We mini-
mized the effect of the small sample size
by using a homogeneous study cohort.
Second, although our study offers physi-
ologic insights into diabetic vascular dys-
function, the ﬁndings were signiﬁcant
during euglycemia and therefore have
limited clinical applications in subjects
who are frequently exposed to ambient
hyperglycemia.
In conclusion, systemic hemody-
namicfunction,includingtheresponseto
COX2 inhibition, is related to ﬁltration
status in diabetic subjects and may reﬂect
general endothelial dysfunction.
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Table 1—Effects of COX2 inhibition and hyperglycemia in type 1 diabetes
Before COX2 inhibition After COX2 inhibition
Hyperﬁltration group Normoﬁltration group Hyperﬁltration group Normoﬁltration group
Euglycemia Hyperglycemia Euglycemia Hyperglycemia Euglycemia Hyperglycemia Euglycemia Hyperglycemia
Biochemistry
Plasma insulin
(pmol/l) 87  51 101  52 98  99 88  100 103  69 105  74 83  49 77  73
Blood pressure
Systolic blood
pressure 114  10 113  8 117  10 116  13 112  10 116  11 119  9 120  9
Diastolic blood
pressure 65  96 2  56 0  56 1  46 2  96 5  76 5  76 6  9
Mean arterial
pressure 83  97 9  67 9  77 9  87 9  98 2  88 3  88 4  8
Heart rate (bpm) 70  11 68  11 61  13 61  10 67  12 64  13 62  11 61  12
Endothelial function
FMD (% change) 5.9  2.3 7.6  2.9 10.2  5.3* 8.3  4.23 8.3  3.9 8.2  2.54 5.8  3.4†‡ 8.1  3.2
GTN (% change) 13.0  3.2 14.2  3.1 11.0  3.7 13.7  7.9 12.1  4.2 14.7  4.9 11.1  4.7 13.9  7.0
Data are means  SD. Clamped euglycemia  4–6 mmol/l; clamped hyperglycemia  9–11 mmol/l. *P  0.003 for FMD during clamped euglycemia in the
hyperﬁltering group vs. the normoﬁltering group. †P  0.006 for the effect of COX2 inhibition on FMD in the normoﬁltering group during clamped euglycemia.
‡P  0.003 for the change in FMD in hyperﬁlterers vs. normoﬁlterers in response to COX2 inhibition during clamped euglycemia.
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